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ABSTRACT 
 
TITLE OF THE ABSTRACT: 
Analysis of factors that help to predict malignancy in patients with 
thyroid nodules presenting to the General Surgery Out- patient 
department in Christian Medical College, Vellore. 
 
DEPARTMENT:                          
 
 
NAME OF THE CANDIDATE: 
 
 
DEGREE AND SUBJECT: 
  
 
NAME OF THE GUIDE:  
Endocrine Surgery, CMC Vellore  
 
 
Vimalin Samuel  
  
 
MS (General Surgery) 
  
 
Dr. M.J Paul 
 
 
 
 
OBJECTIVE : 
 
 
To study and analyse the factors that help to predict malignancy in  
patients with thyroid nodules presenting to the General Surgery Out-  
patient department in Christian Medical College, Vellore. 
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INTRODUCTION: 
 
Thyroid nodules are considered common , as they are found in more than 7 percent of  the 
adult population. However, this incidence goes up even higher if ultra sound is used as a 
screening tool.   
 
Among patients presenting with thyroid nodules, 5%–15% will be malignant depending upon 
age, sex, radiation exposure history, family history and other factors.(1) 
 
Differentiated thyroid cancer (DTC), which includes papillary and follicular cancer, 
comprises of the vast majority(90%) of all thyroid cancers.  The increasing level of detection 
may be due to the increasing patient awareness, use of neck ultrasonography and early   
diagnosis and treatment. These are the trends that are changing the initial treatment and 
follow-up for many patients with thyroid cancer. 
 
The difficult bit is in identifying the thyroid nodules that are malignant and the challenge to 
the surgeon lies in deciding which nodules require surgical excision. 
 
 
 
 
 
 
 
7 
 
 
RELEVANCE: 
 
The incidence of thyroid swellings vary from place to place depending upon which area of 
India, the patient is from. In a tertiary care centre, like Christian Medical College, Vellore, 
thyroid nodules are a common problem because of referrals from a wide geographical source 
with a significant number from the “ goitrogenic belt” of India. In this situation, it becomes 
very important to have a clear idea of the risk factors for malignancy so that the doctor can 
offer an appropriate course of treatment for the patient and the patient is also able to make an 
informed decision. Most of the literature and guidelines that are available have been based on 
studies that been conducted on western population. Does the same hold good for the Indian 
population? 
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AIMS AND OBJECTIVES: 
 
In patients presenting with any nodule of the thyroid, to assess with clinical criteria, Ultra sound 
neck and FNAC so as to predict the likelihood of malignancy: 
a) using a triple assessment , consisting of: 
                        - history and examination 
                        - FNAC of the nodule 
                        - ultra sound neck.  
b) Predict the percentage likelihood of nodules diagnosed as non-malignant on FNAC, 
to  be  malignant on histopathology. 
 
c) To look also at independent risk factors, in ultra sound and FNAC for diagnosis of  
           malignancy. 
         d)   To form a treatment protocol based on triple assessment for any thyroid nodule. 
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Literature review: 
 
CLINICAL EVALUATION OF THYROID NODULES: 
 
The evaluation of a patient with a thyroid nodule consists of three arms; a good history and 
general examination, ultrasonography of the gland and fine needle aspiration cytology of the 
nodule. 
 
History and clinical examination: 
 
There is no doubt that first and foremost, for an evaluation of a thyroid nodule, a detailed 
history and thorough clinical examination will lead the way to a sound diagnosis. 
 
Patients usually present with a large palpable nodule in the neck incidental nodule found on 
imaging studies . Some palpable nodules may not correspond to radiological abnormalities. 
 
Non palpable nodules that are detected on ultra sound or other anatomic imaging studies, 
usually as part of evaluation for other reasons are called incidentally discovered nodules or 
‘‘incidentalomas’’.   Non palpable nodules have a similar risk of malignancy as palpable 
nodules that are of the same size(2). 
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Generally, only the nodules that are >1 cm in size should be evaluated, as they have 
significantly higher risks of malignancy(2). 
 
There are some nodules which are <1 cm in size that may require complete evaluation when 
suspicious ultra sound features, associated palpable lymphadenopathy or previous history of 
radiation to head or neck or history of thyroid malignancy in first-degree relatives(2). 
 
However, in a recent study by Burch HB, Shrestha  M, Crothers BA, they analysed Whether 
the size of the nodule plays a role in predicting malignancy.   
 
During a ten year period (2001 to 2011), 3013 patients had fine needle aspirations of  thyroid 
nodules at the Walter Reed Army Medical Center(3).  The patients who underwent 
subsequent thyroid surgery were included in the analysis(3).  The nodule size was assessed 
by ultrasound measurement of the largest diameter and categorized as 0.5 to 0.9 cm  (group 
A), 1.0 to 3.9 cm (group B) and ≥4 cm (group C)(3).   
 
FNA cytology was categorized by the Bethesda System for Reporting Thyroid 
Cytopathology: benign, atypia (follicular  lesion of undetermined significance), follicular 
neoplasm, suspicious for malignancy, or malignant. All categories except for benign were 
considered positive for calculation of the sensitivity and specificity of the F 
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NA.  There were 35 nodules in group A, 533 nodules in group B and 127 nodules in group C.  
The malignancy rate based on surgical pathology was 18.6%  (129 of 695 nodules)  and did 
not differ among the size categories.  
 
 
The malignancy rate was 23% in both men and women. (3) So this leads us back to the 
question of whether size matters?  Traditionally, the teaching has been that, nodules greater 
than 4cm are at high risk for malignancy.  
 
 
 However with the advent of imaging and detection of smaller cancers, size does not appear 
to be a risk factor. The most pronounced environmental risk factor for thyroid cancer is 
exposure to ionizing radiation.  Ionizing radiation is either due to medical treatment  
(childhood radiation therapy for benign or malignant disease, adult treatment of 
malignancies) or nuclear fallout (atomic bomb / testing survivors, nuclear energy accidents ). 
 
 
Ionizing radiation may exert this effect through several changes to the cell, 
includingGenomic instability.  The effects of ionizing radiation are most pronounced in 
children,  especially those younger than 10 years old at the time of exposure.  The latency 
Period of developing cancer from this exposure is approximately 10 years for patients.  
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Having external beam radiation exposure to less than 5 years for victims of the Chernobyl 
accident and the increased risk persists for 30 to40 years. Exposure to Ionizing radiation has 
been shown to increase the risk of malignancy for a thyroid Nodule to 30% to 40%.  
Furthermore, this risk of malignancy is increased regardless of nodule number and size and 
multifocal malignancy is found more than half of  the time. A history of prior radiation 
exposure mandates initial total thyroidectomy.  
 
 
The gender-specific distribution is equal in those older than 65 and given that overall two-
thirds of cancer cases are women, there would seem to be a link between reproductive 
hormones and the development of thyroid cancer. Estrogen has been linked as a stimulus for 
genomic instability and this may be how it exerts its mutagenic effects on the thyroid. Studies 
have yet to conclusively link traditional carcinogens such as alcohol and tobacco to the 
development of  well differentiated thyroid cancers. Data are conflicting as to what role  
iodine - rich versus iodine - deficient diets play in the development of thyroid cancer.  
 
Countries with iodine-rich diets such as the United States and Sweden have slightly increased 
incidence of papillary cancer and countries with iodine-deficient diets such as Switzerland 
and Australia have slightly increased incidence of follicular thyroid cancer.(4)  
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 A dominant or solitary nodule is more likely to represent carcinoma than a   Multi nodular 
gland with an incidence of malignancy from 2.7 to 30% and 1.4 to 10% respectively(1).  Yet, 
the overall risk of malignancy within a gland with a solitary nodule is approximately equal to 
that of a multi nodular gland due to the additive risk of each nodule .  Important elements in 
the patient’s history which  increase  the  likelihood  of  malignancy  include  reports of rapid 
growth,  dysphagia,  dysphonia,  male gender, presentation at extremes of age (less than 20 
years or more than 70 years) and a family history of medullary thyroid carcinoma or multiple 
endocrine neoplasia(1) . 
 
Patients must be asked for any family history of either benign or malignant thyroid diseases. 
Although not well defined, there most certainly exists a genetic component to thyroid 
cancers. In fact a family history of thyroid carcinoma may increase an individual’s risk 3-fold 
when a parent has the disease and up to 6-fold if a sibling has the disease.(4) 
 
 
The familial medullary thyroid cancers, multiple endocrine neoplasia 2, The familial 
papillary thyroid tumours, familial polyposis coli, Cowden disease, Gardner’s syndrome even 
though they are not common, must be considered.(5). 
 
Papillary thyroid cancers and follicular thyroid cancers have distinct genomic and proteomic 
signatures. Pathways are now emerging that demonstrate how these differences play a role in  
governing tumor biology. Mutations that involve RET, NTRK1, BRAF, PPARγ, or Ras can 
be detected in almost 70% of cases. There are at least 12 different RET mutations, known as 
PTC/Ret chimeric onco proteins, which seem to be an early event in thyroid tumorigenesis, 
14 
 
with series showing a high prevalence in papillary micro carcinomas and also a high 
proportion of the post-Chernobyl childhood-induced papillary thyroid carcinomas. 
 
 
BRAF mutations are seldom found in radiation-induced cancer. These mutations are 
postulated to produce a more aggressive phenotype of papillary cancers as they are found in 
many of the more poorly differentiated subtypes. Follicular carcinomas have mutations in   
PPARγ (rarely found in papillary cancers), AKT pathways, and Ras. 
 
 
Symptoms like difficulty in breathing, neck tenderness, pain, difficulty in swallowing or even 
change in voice can be attributed to thyroid problems, but in many patients, these symptoms 
are due to non thyroid diseases. In those patients that are symptomatic, evaluation must start 
with getting a proper history, doing a full physical examination, reassuring the patient and for 
choosing the correct laboratory tests.  
 
 
Acute pain is most often because of  hemorrhage in to a nodule that is cystic in nature. 
However, patients that present with rapid increase in size of the thyroid nodule, lymphoma or 
anaplastic carcinoma  of thyroid must be considered. 
 
 
The beginning and slow progress of neck symptoms and signs are usually because of 
compression of the structures in the neck and upper chest cavity (oesophagus and trachea), 
which happens in those thyroid nodules that are found in large goiters.  
15 
 
 
 
 
 
The features of compression are not so common and are found in the elderly or middle-aged 
having a long - standing multi nodular goitre. The goiter that is growing downwards into the 
superior mediastinum can result in partial or complete obstruction of the chest inlet,  causing 
venous obstruction. When the patient is made to raise his or her arms above the head ; i.e. 
Pemberton’s sign, more narrowing of the chest inlet is produced which is followed by over 
filling of the external jugular veins and facial congestion. 
 
 
If this is seen when there is a smaller goiter, the features of tracheal compression.  May 
suggest an underlying cancer.  Differentiated thyroid cancers will usually not cause airway 
obstruction or vocal cord palsy or oesophageal problems but even if there are no symptoms, it 
does not rule out malignancy.(5) 
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Physical examination: 
 
Physical exam findings that increase the concern for malignancy include: 
 
• Nodules that are larger than 4 cm in size (19.3% risk of malignancy) 
 
• Firmness to palpation 
 
• Fixation of the nodule to adjacent tissues 
 
• Cervical lymphadenopathy 
 
However, these findings are very often limited by certain factors such as the patient’s body 
habitus, as well as an inherent variation between physicians and their assessment of nodules 
so much so that precise measurement using imaging is a must of evaluation of a thyroid 
nodule.(1) 
 
A hard nodule is suspicious as traditionally goitre has always been described as firm. 
However a benign multi nodular goitre may turn hard because of calcifications or 
hemorrhage.  
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Fixity of a nodule is because of its infiltration into surrounding structures.  This feature is 
seen in malignant thyroid nodules and fixed swelling almost always require excision. 
 
 
Cervical lymphadenopathy in the Ipsilateral level 3 or 4 is the most specific pointer to 
malignancy in a thyroid nodule; rarely this may prove to be red herring as in a patient with a 
thyroid swelling, they may have associated reactive hyperplasia of a the corresponding 
draining lymph nodes especially in the presence of autoimmune thyroiditis. However, it is 
essential to assess these lymph nodes with an ultra sound of the neck and plan the surgery 
with an option of doing a neck dissection with a frozen section of the lymph node if 
necessary. 
 
Role of biochemical evaluation in thyroid nodules: 
 
The initial investigation that is necessary for all the patients presenting with a clinically 
palpable solitary lesion is an assessment of the biochemical properties of the thyroid gland as 
clinical examination in itself is not enough to establish thyroid dysfunction(6). A low level of 
serum thyroid stimulating hormone will forewarn the clinician of the possibility that the 
solitary lesion clinically found may be a toxic nodule.  
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The workup proceeds with total or free thyroxine (T4) and total tri iodothyronine (T3) to 
better evaluate the hyper thyroid state. This occurs in approximately 10% of patients with a 
solitary thyroid nodule and is suggestive of a benign hyper functioning adenoma(1). On the 
other hand, it may even be part of a toxic multi nodular goitre or it may be a solitary nodule 
in a case diagnosed with Grave’s disorder.   
 
FNAC should  be  avoided  as an ‘atypical’ result in biopsy may be reported due to the hyper 
cellularity that is often associated with  lesions that function autonomously. A radionuclide 
scan is considered as the   investigation of first choice(6). 
 
Toxic multi nodular goiters may however harbour both hyper functioning and cold regions. 
Thyroid nodules in those with Graves’ s are usually found as malignant in around  9% of the 
cases(5). 
 
Ultrasonography(US) 
 
Ultrasonography has proved to be the imaging of choice for thyroid nodules. It can identify 
nodules that are too small to be palpated, the presence of multiple nodules, central, or lateral 
neck lymphadenopathy and also provides an accurate measurement of nodule diameter for 
interval monitoring. 
 
 
 
 
19 
 
 
Fujimoto et al in 1967 were the first to describe detection and characterization of 
thyroidnodules by US.  From then on, several studies have been designed in order to establish 
the validity of thyroid ultra sound in making a diagnosis of either a benign or a malignant 
thyroid nodule.   
 
Moreover, the rapid development of ultra sound equipment during recent years, with the 
availability of 7–13-MHz high-frequency transducers, has allowed the detection of very small 
thyroid lesions (2–3 mm)(7).  Non - palpable thyroid nodules are detected by ultrasound in 
13–50% of the general population. 
 
Thyroid ultrasound features that are most commonly found in malignant thyroid nodules are 
Micro calcifications, hypo echogenicity, absent halo or irregular margins, solid lesions, intra 
nodular vascularity and the nodule that is taller than wide. These features, if taken by 
themselves alone, are very poor predictors of malignancy. However if they are described 
together, the specificity will go up at the cost of sensitivity(7). 
 
To visualize the thyroid gland optimally, the patient is placed in the supine position with a 
Pillow underneath the shoulders to extend the neck slightly, allowing the head to rest on the 
examination table.  
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In older patients or those who have degenerative changes in the neck, small towels can be 
placed under the head to the level where the patient is most comfortable while still allowing 
access to the neck. The thyroid gland is then imaged in transverse and longitudinal views 
with a high frequency (10–15 MHz) linear transducer. The highest frequency is used while 
still allowing adequate sonographic penetration. 
 
A thyroid nodule on US is defined as a region of parenchyma that is sonographically distinct 
from the remainder of the thyroid and located within the confines of the echogenic thyroid 
apsule. When a nodule is detected, its size should be measured in three dimensions and the 
location within the thyroid gland (upper pole, mid-gland, lower pole, right or left) should be 
noted by the sonographer. 
 
 
 
Nodule size: 
 
Inspite of extensive research, the worldwide consensus is that, most ultra sound features of 
malignancy applies to nodules that are greater than 1cm in size. Although the American 
Association of Clinical Endocrinologists and American Thyroid Association guidelines 
continue to use 1 to 1.5 cm as a practical threshold for selecting nodules for FNA, it has been  
shown that size is not a good predictor of malignancy(8).   
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Hypoechogenicity: 
 
 An echogenic appearance is commonly associated with follicular neoplasms, both benign 
and malignant, but can also be seen in papillary cancers. ‘‘Marked hypoechogenicity’’ is 
defined as echogenicity less than that of adjacent musculature, is a more specific appearance 
for thyroid carcinoma, but this feature has a fair amount of inter observer variation.(8) 
 
                                        
 
Transverse gray-scale mode image of a normal thyroid gland, which is uniformly echogenic  
relative to overlying strap musculature.(9) 
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Longitudinal image of hypo echoic papillary cancer (arrow) with irregular margins.(9) 
 
Calcification: 
 
Calcifications have been found in papillary, medullary, and anaplastic thyroid carcinomas as 
either psammoma bodies or as amorphous granular deposits. Of all the sonographic features 
associated with thyroid malignancy, micro calcifications are the most specific. Micro 
calcifications are defined as punctuate echogenic foci without acoustic shadowing or 
associated comet-tail artifact. The positive predictive value of a finding of microcalcifications 
in a thyroid nodule ranges from 24.3% to 70%.(7) 
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Transverse image of right thyroid lobe in papillary cancer which shows innumerable. Micro 
calcifications create a ‘‘snowstorm’’ appearance.(9) 
 
 
Vascularity: 
Almost all solid nodules display some flow on colour Doppler interrogation with current 
generation Ultrasound equipment. In general, a peripheral flow pattern tends to be a feature 
of benign nodules and malignant nodules tend to have internal vascularity,  but there is 
considerable overlap. Although marked internal vascularity was more often present in 
malignant than benign nodules, more than half of nodules with internal hyper vascularity 
were benign(7). 
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Transverse image shows flow in peripheral hypo echoic capsule and internal vascularity.(9) 
 
 
 
Composition: 
Every nodule must be assessed with the percentage of nodule which is found to be solid 
against the percentage of the nodule that is found to be cystic. Lesions may be categorized 
semi quantitatively, depending upon the fraction of cystic and solid components. This can 
also be done using descriptive terminology that is found on the pre dominant composition  ie: 
solid, pre dominantly solid or mixed solid with cystic or pre dominantly cystic with cystic.  
The nodules that are solid or mostly solid have a greater risk of turning out to be malignant 
than the mixed or pre dominantly cystic type of nodules. The nodules that are found to be 
cystic or mostly cystic have a low risk of malignant potential. Lesions that have a mixed 
composition have been found to have a lower risk of malignancy(8). 
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Image obtained with conventional high resolution transducer shows small cystic areas in  
lower portion of nodule.(9) 
 
Height of the nodule: 
 
By analogy with breast carcinomas, some studies have shown that a shape taller than wide 
was 92.5% specific for malignancy. This feature had fairly low (32.7%) sensitivity.  
However, this finding was not definitively confirmed in all series(7). 
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Abnormal cervical lymph nodes: 
 
Ultra sound evaluation of any lymph node will depend upon on its vascularity, shape, sizeand 
architecture.  The ultra sound markers of cancer are echotexture that is heterogenous, areas of 
calcifications and areas of cystic change within the node. A round node or a node that causes 
mass effect is at a higher risk of turning out malignant.  Generally, the nodal size is not a very 
reliable indicator for malignant change in a node than the shape and the architecture, even 
though the risk of the node being malignant increases when the size of the node increases. 
Hence, any node must be looked upon with suspicion if they are found to be greater than 
7mm in the short axis or if there is loss of fatty hilum(7)(8). 
 
 
 
 
 
 
 
 
 
 
 
 
27 
 
 
 
 
 
 
 
 
 
Longitudinal image of metastatic papillary carcinoma with cystic change in cervical lymph 
node.(9) 
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Recent advances: 
Ultra sound evaluation of the thyroid nodule has recently under gone a sea of change with the 
 introduction of the TIRADS score. Horvath and his collegues made six groups and named it 
the Thyroid Imaging Reporting and Data System (TIRADS) which were founded on ten ultra 
sound patterns.  
 
 
They then calculated the frequency of cancers in every group: 0% in TIRADS 1 and 2, <5% 
in TIRADS 3, 5% to10% in TIRADS 4A, 10% to 80% in TIRADS 4B and >80% for 
TIRADS 5. They then went on to suggest that patients with nodules rated TIRADS 4 and 5 
must have biopsies(10). Their results showed a high power of discrimination however the 
validity of the study has not yet been confirmed. 
 
In April 2012, Cheng SP, Lee JJ, Lin JL, Chuang SM, Chien MN, Liu CL from the Surgical 
department of Mac kay Memorial Hospital in Taiwan, in the Institute of Pharmacology at the 
Taipei Medical University in Taiwan published their results including 498 nodules in 437 
patients that went on to have thyroidectomies. Two surgeons with two endocrinologists 
separately reviewed the sonology images. The main reason for this study was to assess the 
inter - observer variability along with the accuracy. 
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A moderate to substantial inter observer agreement was found for the final assessment Group 
that was kappa = 0.6. The results showed that the sensitivity and specificity and negative 
predictive value were 94 percent, 43 percent and 96 percent each. The positive predictive 
values in the groups 4 and 5 were 32 percent and 60 percent each. The calculated sensitivity 
came to 92 percent, 99 percent, 96 percent and 89 percent. The specificity calculated was 25 
percent, 37 percent, 41percent and 62 percent for tumour sizes of <2 cm,  to 3, 3 to 4 and  >4 
cm, respectively. 
 
They concluded that the TIRADS is useful but definitely not the most optimal tool used for 
reporting in thyroid swellings. They also felt that the size of the tumour has an important role 
to play in inter -  observer agreement and performance in diagnosis. 
The role of thyroid elastography is being investigated as a modality of investigation for the 
thyroid gland. The basic principle of elastography is that tissue compression produces strain  
(displacement) within the tissue that which is found to be small in hard than in soft tissues, 
and is then scored by measuring the amount of distortion that is produced by the beam of 
ultra sound after applying an external force(8). 
 
The principle of ultra sound elasto graphy is to see two ultrasonographic pictures, before and 
after the tissue is compressed by the probe and to see tissue displacement when the beam 
propagates(9). The combined auto correlation method dedicated software is programmed to 
give an accurate measurement of the distortion of tissues. 
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The Ultra sound elastography image is matched with an elasticity colour scale and classified 
 by using the elasticity score of Ueno and co-workers.(9) 
 
Elasticity score (9) 
 
 
The predictivity of Ultra sound elastography was shown to be independent of the nodule size, 
with high sensitivity and specificity being observed also in nodules < 1 cm, independently 
from the position of the nodule within the thyroid lobe(9). Available data suggest that ultra 
sound elastography is the best available non-invasive tool for the evaluation of thyroid 
nodules, comparable to fine needle aspiration. 
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Radioisotope imaging 
 
Radioisotope scanning has been used to determine whether a thyroid nodule is functioning. 
However, it does not provide an accurate measurement of size. The radioisotopes that have 
been used are technetium (99mTc), I 123 and I 131 and although the same information is 
obtained with similar amounts of radiation exposure, radioiodine is the preferred option. Of 
these, about 80 to 85% of thyroid nodules are cold and about 10% of these nodules are 
malignant. The hot nodules account for 5% of all nodules and the likelihood of malignancy is 
less than 1% for these nodules. Everything put together, the sensitivity for the diagnosis of 
thyroid cancer is 89 to 93%, specificity is 5%, and the positive predictive value of 
malignancy is only 10.  The use of radioisotope for performing thyroid scans has been nearly 
abandoned in the initial workup of a thyroid nodule. 
 
Computed tomography (CT) and magnetic resonance imaging (MRI) 
Both of these modalities have almost no role in evaluation of any thyroid swelling and are 
very rarely indicated in the initial workup. However, they both have excellent (100% 
sensitivity) for evaluating the extent of large sub sterna or retrosternal goitres which may be 
compressing or infiltrating nearby structures(1).  It is imperative to note that iodinated 
contrast material utilized for routine CT scans prevents scintigraphy or administration of 
radioactive iodine (1) therapy for atleast a period of 1 to 2 months and is avoided where early 
ablation may be required. Gadolinium contrast used with MRI does not interfere with thyroid 
uptake of radiotracer, but it is significantly more expensive than CT or ultrasound(1) MRI 
images are also of low contrast, making it difficult for surgeons to interpret and use as a 
roadmap for a difficult procedure. 
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18F-fluorodeoxyglucose positron emission tomography-computed tomography (18FDG-
PET/CT) 
18FDG-PET/CT is being used extensively in oncology for staging, evaluation of treatment 
response and detecting recurrences on the principle that malignant cells have a higher uptake 
of 18 FDG due to increased metabolic demands in comparison to normal tissues. In general, 
the appearance of the images and maximum standard uptake value (SUV max) can be used to 
differentiate between malignant and benign lesions. This does seem to hold good for thyroid 
nodules as there is no significant difference in the SUV max between benign and  malignant 
18FDG - avid nodules(1).  
 
The role of 18FDG - PET/CT in reducing the need for diagnostic thyroid lobectomy for 
indeterminate lesions has been studied to be negative predictive values 95 to 100%. While 
such preliminary studies are promising, further research is needed before observation could 
universally be recommended over surgery for non-18FDG-avid thyroid nodules with 
indeterminate FNA cytology(1). Even though 18 FDG-PET/CT does not play a role in the 
workup of a nodule,any 18 FDG - avid thyroid nodule found incidentally deserves a thorough 
workup for malignancy. 
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Fine needle aspiration cytology and the Bethesda system: 
 
The procedure of FNAC and cytology examination was first developed by Ellis and Martin in 
the year 1930. At present, FNA cytology or thyroid gland biopsy has been accepted 
everywhere as the step with most importance in the pre operative evaluation any lesion in the 
thyroid gland. About 2,50,000 to 3,00,000 fine needle biopsies have been estimated to have 
been done over a period of one year in the United States.   As the fine needle aspiration gives  
 
the most accurate information regarding the composition of cells in any thyroid lesion, it has 
always been seen as the gold standard in diagnosis that will change subsequent decisions 
regarding management.  
 
The guidelines for practise formulated by the American Thyroid Association have 
recommended that fine needle aspiration must be one of the early diagnostic investigations 
because it is highly reliable for diagnosis and is cost effective(11).  Fine needle aspiration 
cytology plays an important part in the assessment of a bio chemically eu thyroid nodule.  It 
decreases the need for surgery in patients that are diagnosed to have benign nodules.  
 
It also categorises patients that are diagnosed to have thyroid cancer to the needful operation.  
Prior to routine cytology, the percentage of operated thyroid swellings that turned out to be 
malignant was 14%.  With the present fine needle aspiration cytology practise, the percentage 
of surgically excised lesion that turn out to be cancers surpasses 50%(12). 
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Unfortunately,  FNAC of any thyroid nodule is far from being perfect. It can provide results 
that are useful for diagnosis in only around 80% cases. The sensitivity and specificity are 
about 83% and 92%, respectively(11). 
 
 
Before a FNAC is done, the gland must be thoroughly felt, the nodule that is for aspiration 
must be identified. This procedure must be told to the patient in a satisfactory manner and the 
patient’s queries must be addressed. The patient is made to lie down flat on the examination 
table and extending his/her neck completely and a support is placed below the shoulders. 
Good lighting must be present.  
 
 
The skin surface is cleaned with spirit. Then the patient is told to lie still during the placement 
of the needle. Anaesthesia is usually not needed.  Usually a 27 gauge or 25 gauge 1.5 inch 
needle fixed with a 10mL disposable syringe is required. Some may use a mechanical holder 
for the syringe.  
 
The needle is then plunged into the lesion without the use of suction and making sure that the 
tip of the needle is within the lesion. Suction is then applied while the needle is moved out 
and into the nodule. This motion helps to separate cellular material which will be sucked in to 
the needle. In a few seconds, the aspirate is seen within the hub of the needle. 
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When this happens. the suction is stopped, the needle can be taken out and smears can be 
made. Syringe is then separated from needle and air is sucked in by withdrawing the plunger. 
The syringe is  re attached to the needle and a drop of the material that is aspirated is then put 
onto glass slides. 
 
 
 The smears are made using two glass slides, in a similar method to making blood smears. 
The slides thus prepared can be dried by air or fixed by submersing them in 95% alcohol for 
Papnicolaou stain. In some centers, automated cytology machinery like Thin Prep are used 
where the specimens are kept in a solution and seen later at the lab. Two or four passes are 
made from various sites in the nodule. In each aspiration, two or four slides can be prepared.  
 
 
Non- aspiration biopsy of the nodule may be done. For this technique, a twenty five gauge 
needle is held as one would hole a pencil, at the hub , and is then inserted in the lesion to be 
aspirated. After the aspirate has flown into the hub, it is withdrawn. 
 
 
The material that is collected into the shaft is put on slides. The smear is the prepared as 
previously described . 
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As soon as the needle is withdrawn, there must be immediate and gentle compression at the 
site of aspiration. This is to prevent formation of a hematoma. If the patient is comfortable 
and there are no problems, the patient can be allowed to leave. 
 
 
The concern with Fine needle aspiration or biopsy is the number of falsely negative results, 
that may result in inadequate surgery and further create complications in management. The 
falsely negative results have been described as benign cytology in the FNA but provide a 
histological surprise by being diagnosed as carcinomas after surgery. The rates of these 
falsely negative results vary between 1.5%  and 11.5% in various study series(11). 
 
 
The reasons for these falsely negative results are mostly not clear. Some of the solutions 
include the use of ultrasound in guiding proper FNAC placement and aspiration of different 
nodules have been proposed to lower false negative reports.  Sampling that is not adequate is 
one of the most crucial issues that changes the accuracy of  the cytology other than human  
errors. Then, the error in the method of sampling usually occur when there are many nodules 
and when benign lesions are biopsied instead of the malignant ones(11). 
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Fine-needle capillary sampling — Fine-needle capillary sampling (FNC, also called fine-
needle nonaspiration biopsy) is a variation of FNA in which the sample is obtained by 
repetitively moving within the nodule a 25- to 27-gauge needle that is not attached to a 
syringe. After the needle is removed from the nodule, a syringe containing air is used to 
express the sample on a slide, which is smeared, stained, and submitted for cytologic 
interpretation. An FNA done with the syringe attached to the needle but with no negative 
aspiration pressure provides similar results.(13) 
 
 
FNA versus FNC — The negative aspiration pressure used for FNA may result in more 
tissue damage and bleeding than FNC. This is a potential problem since blood and fibrin can  
obscure cells and therefore limit the ability to interpret the specimen. The relative efficacy of 
these procedures was evaluated in a study of 104 thyroid aspirates. 
 
 
 The specimens obtained by FNA were significantly more likely to be non diagnostic than 
those obtained by FNC (16 versus 6 percent). In a second report, the percentage of non 
diagnostic samples at a variety of body sites was the same with both techniques, but the 
cytologic smears obtained with FNC were of higher quality.(13) 
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Complications — Local pain and hematomas are the most common complications, while 
serious adverse events are rare. This was illustrated in a systematic review of 13 studies 
including 18,156 individuals undergoing thyroid biopsy. The following findings were noted: 
 Local pain and/or discomfort were minor, transient, and well-tolerated, but several 
studies reported subsets of patients (2 to 8 percent) with moderate pain lasting up to 
several days. Pain was more common when deep-seated, non palpable nodules were 
biopsied, but the procedure rarely had to be discontinued because of patient 
discomfort. Local lidocaine  anaesthesia can help minimize pain. 
 
 There was inconsistency in the reported frequency of hemorrhage/hematomas during 
or after thyroid biopsy with a range of 0.3 to 26 percent. Small to moderate-sized 
hematomas were managed with cold compresses and almost always resolved 
spontaneously within several days. Massive hematoma with airway obstruction was 
seen in only a few cases. 
Other complications are rare and include acute transient thyroid swelling, infection, tracheal 
puncture, needle track seeding (ie, tumor implantation), and recurrent laryngeal nerve palsy 
with vocal cord paralysis. In another series, recurrent laryngeal nerve injury occurred in 4 out 
of 10,974 biopsies (0.036 percent), which resolved in all cases within six months.(13) 
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It is very important that cyto pathologists are able to communicate thyroid FNA reports to 
referring doctors using terms that are unambiguous and are helpful in making management 
decisions.  
 
Historically,  the terminology that have been used for thyroid FNA has always been a 
problem. It differed between laboratories leading to utter confusion and preventing sharing of 
data among various institutions. 
 
Prior to the standardization of FNACs with the Bethesda system, the categories that were 
adopted were non diagnostic, benign, follicular / Hurthle neoplasm, suspicious for 
malignancy, and malignant. 
 
In order to address these terminology related issues of thyroid FNA,  the Bethesda System for 
Reporting Thyroid Cytopathology was made in 2007. To have clear communication, the 
Bethesda System suggests that every report begins with a “general diagnostic category”.  
There are six general diagnostic categories. Some categories have 2 alternative names. Each 
one of these categories carries an implied risk of cancer which ranges between 0% to 3% for 
the benign group to almost 100% in the malignant group. This  entire process connects to a 
management guideline that is rational and appropriate.  
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The six categories are as given below. 
 
(12) 
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(14) 
 
Non diagnostic or Unsatisfactory: 
 
 Colloid nodules that display macro follicles 
that are bordered by epithelial cells of thyroid origin. These nodules are well circumscribed and does not possess 
a fibrous capsule(15). 
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The adequacy of cells in every FNAC done, should be properly evaluated. Specimens that are 
inadequate are reported as “non diagnostic” (ND) or “unsatisfactory” (UNS). This also 
applies for groups of samples that are deemed not satisfactory because of excessive blood and 
improperly made smears and an inadequate number of follicular cells. If a thyroid FNAC 
specimen has to be satisfactory for evaluation, the minimum requirement is atleast 6 groups 
of benign follicular cells, each group comprising of at least 10 cells. 
 
As usual, there are exceptions. Any sample which has lots of colloid is said to be adequate, 
even though six collections of follicular cells are absent.  Any specimen that has a sparse 
number of cells with a lot of colloid is usually a predominantly macro follicular nodule and is 
almost always benign. When a particular diagnosis can be given and when there are any 
atypical cells, the sample is by implication, appropriate for further evaluation. 
  
Non diagnostic or unsatisfactory results are seen in 2% to 20% of the patients,  but ideally it 
should not exceed 10% of the FNACs, leaving out samples that are made almost entirely of 
macrophages. 
 
A repeated aspiration with the guidance of ultra sound is recommended for this category and 
those FNACs that are clinically or sonographically worrying and is diagnostic in about 50% 
to 88% of cases. Surgical removal of the thyroid gland is one of the options for nodules that 
have been non diagnostic or unsatisfactory as ten percent are found to be malignant(12). 
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Benign: 
 
 
An area with nodular hyperplasia and a colloid nodule with macro follicles and focal hyperplasia that is suggestive 
of a benign nodule.(15) 
 
The benefit of a thyroid FNAC enables the surgeon to make a diagnosis of a benign lesion as 
correctly as possible thus avoiding the need of an unwanted surgery.  A “benign” diagnosis is 
seen in about 60% or 70% of FNACs from the thyroid gland. 
 
A benign interpretation carries a low risk of being falsely negative (0% to 3%), but these 
individuals are nevertheless re assessed by ultrasound and palpation every six to eighteen 
months. When the nodule that is being followed up shows rapid growth or  any “suspicious” 
change on ultra sonography, then a repeat FNA must be considered(12). 
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Atypia of Undetermined Significance / Follicular Lesion of Undetermined Significance: 
 
 
Nodule that shows micro follicles and is surrounded by an even fibrous capsule. There is no capsular or vascular 
invasion.(15). 
 
 
Some epithelial cells found in follicular arrangement that suggests an adenoma, which can be from a follicular 
carcinoma.(15) 
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Some cytologies may not be classified with ease into the categories of benign or suspicious or 
malignant. These are the cases that have been found to represent a small group of cytologies 
and are reported as atypia of  undetermined significance (AUS) or follicular lesion of 
undetermined significance in the Bethesda System. 
 
The risk for malignancy for an nodule that has been labelled as AUS is very tough to 
establish as only a small proportion of patients in this group have had surgery and follow up. 
The patients who have had an operation form a very focussed group of patients who have had 
FNACs with repeated AUS reports or in those patients who have clinical or sonological 
lesions that are worrisome. In this group, about 20% to 25% patients having atypia of 
undetermined significance prove to be of malignant nature after surgery(12). 
 
Follicular Neoplasm / Suspicious for a Follicular Neoplasm: 
 
A Hurthle cell tumor, seen in the lower half of photograph showing well circumscribed margins established by an 
intact fibrous capsule. This is a Hurthle cell tumour of low malignant potential(15). 
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The intention of this group is to find those nodules that maybe follicular cancers and guide 
towards an operation. FNAC can be used to diagnose many thyroid diseases (eg: papillary 
cancer or lymphocytic thyroiditis), however, in regards to follicular carcinoma, it is often 
used as a tool for screening. 
 
The majority of Follicular neoplasms/suspicious of follicular neoplasm cases turn out as 
Follicular adenomas or as adenomatoid nodules of a multi nodular goitre, which are more 
common than follicular cancer.  Of those that are proven to be malignant, many are Follicular 
carcinomas. However a significant proportion of these are follicular variants of papillary 
carcinomas(12). 
 
Suspicious for Malignancy: 
 
 This is a follicular variant of papillary carcinoma with the 
typical vesicular nuclei and haemorrhage in the follicular lumens(15). 
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Many of these cancers, especially papillary cancer of the thyroid gland, may be precisely 
diagnosed with almost 100 % accuracy by FNAC. However , the nuclear, architectural 
metamorphosis of a few papillary cancers are focal and difficult to pick up. As is most 
commonly seen in the follicular variant of papillary cancers, which may be difficult to 
differentiate from a benign follicular nodule. 
 
Nodules that are labelled as suspicious for papillary carcinoma of the thyroid gland are 
removed either through a lobectomy or a total thyroidectomy.  Many of these (60%-75%) 
prove to be papillary carcinomas and the rest are usually follicular adenomas(12). 
 
Malignant: 
 
 
Papillary carcinoma thyroid. The structure is made of complex fibro vascular core of structures that are covered 
by crowded, overlapping, vesicular nuclei which are artifacts of fixation. Little colloid is seen. Such histologic foci 
may be encapsulated or sclerosing, invasive, or multi centric.(15) 
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This group malignant is usually used when the cytology and morphology are diagnostic of 
malignancy. The description that is given below are those that are used to sub categorise the 
cancer and help to conglomerate the results in any special studies.  About  3% to 7% of 
FNACs have these confirmative features of cancer and these are mostly are papillary 
cancers(12). 
 
 
 Medullary carcinoma thyroid with amyloid stroma(15) 
 
 
. 
Large cell lymphoma thyroid(15) 
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Anaplastic carcinoma of thyroid with pleomorphic giant tumour cell nuclei(15). 
 
 
Recent studies: 
 
There are no doubts about the clinical features that suggest an increased risk of malignancy in 
any thyroid nodule. They have been described time and time again in various surgical text 
books and further discussion will not be necessary. However, the move to introduce the 
Bethesda system of reporting for FNACs of thyroid nodules has been fairly recent. After the 
introduction of the Bethesda system, there have been few studies for validation and literature 
as regards experience with the system in various centers.  Atypia of undetermined 
significance group has been of particular interest.  
 
In a study conducted at Christian Medical College, Vellore (not yet published), out of 1018 
patients operated for thyroid nodules during the study period,  404 (39.7%) were follicular 
lesions. Mean (+SEM, range) age of patients was 41 years (+ 0.78, 12 -78) and M:F were 1:4.  
FNAC showed suspicious for malignancy in 30% (n=43) patients based on higher cellularity, 
nuclear atypia and thick scanty colloid (p0.001).  FNAC was suggestive of benign in 100 
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patients but finally turned out malignant on histopathology.  Lesions with nodule size > 3cm 
had 51% malignancy rate (p0.004). The most common histological variants were papillary 
thyroid cancer (39.2%) including classical (20%), follicular (18%) and micro carcinoma 
(1.2%) variants followed by nodular hyperplasia (19.3%), follicular adenoma (4%) and  
follicular carcinoma (3%). Completion surgery was needed in 47 patients.  
The conclusion from the above study was that nodular hyperplasia & papillary thyroid cancer 
were most common histological variants in follicular lesions. This supports surgical resection 
for “suspicious for malignancy” & “follicular neoplasm”, selective use of surgical 
intervention for “follicular lesions - probably benign” and continued efforts to define unified  
terminology. 
In 2009,  Nayar  R and Ivanovic  M from the Department of Pathology, Northwestern 
University, Feinberg School Of Medicine, Chicago, Illinois published a retrospective study 
on 5194 thyroid nodules. Their conclusion were: 
The Indeterminate category comprised of 18% of all FNACs. Cytology was followed up in 
21 percent of indeterminate patients in which 58 percent was benign / negative and did not go 
on to surgery based on the cytology alone. 
Surgical follow up in 46 percent of indeterminate cases showed 52 percent were benign / 
negative and 42 percent were follicular or Hurthle cell adenomas. The surgical report of 
malignancy in such cases was low (6%) when seen against the Follicular neoplasm group, 
which was 14 percent ,  more than two times the indeterminate category and the suspicious of 
malignancy group which was 53 percent (almost nine times that of the indeterminate 
category). 
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The conclusion that they reached was that a 6-tier reporting system for thyroid FNA was 
effective for determining which patients needed surgery versus follow-up FNA and also 
guided the clinician on the extent of surgery(16). 
 
 
Another study was published in May 2012 by Wu HH, Rose C, Elsheikh TM from 
Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, 
Indianapolis, Indiana.  They applied the Bethesda terminology in 1,382 thyroid cytologies in 
a community setting, which included 539 cases of Benign (39 percent), 376 cases of atypia of  
undetermined significance (27.2 percent), 116 cases of follicular neoplasm (8.4 percent), 37 
cases of  malignant (2.7 percent), 36 cases of suspicious of malignancy (2.6 percent), and 278 
cases of inadequate FNAs (20.1 percent). 
 
 
221 cases (16 percent) of thyroid cytologies had  follow up thyroid surgeries. On follow up 
based on histology, the chance of malignancy was benign 3%, atypia of undetermined 
significance 6%, follicular neoplasm 22%, suspicious of malignancy 56%, and malignancy 
100%.  
 
 
The conclusion that they reached were that classification and recommendation for follow up 
in the Bethesda classification are accurate for every category. Both benign as well as atypia 
of  undetermined significance are lesions of low risk and carry a low probability for 
malignancy. Follicular neoplasms indicate a greater rate for malignancy but an intermediate 
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risk for malignancy while those lesions that are suspicious of malignancy carry a high risk for 
malignancy(14). 
 
 
Most the studies that have been published in relation to the Bethesda system have been single 
center, retrospective studies without ultra sound and clinical correlation.  Further more, there 
are no data available on the Indian population. 
 
 
In another study from the Department of Head and Neck Surgery at the Memorial Sloan 
Kettering Cancer Centre, New York and Cleveland Clinic, Cleveland that was published in 
2010 a nomogram to that will predict the likelihood of malignancy in the evaluation of any 
thyroid nodule was proposed.(17)  
 
 
Patients presenting with thyroid nodules who under went ultrasonography and guided 
aspiration with thyroidectomy at the institutions during the period between 2007 and  2008 
were recruited. The records along with their bio chemical reports, pathology results, 
ultrasonography images with cytology was reviewed. The malignancy risk was then 
calculated using a multi variate logistic regression(17). 
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The charts of 158 cases that had 190 lesions were then reviewed(17).  Eighteen cases were 
then excluded for various reasons. 
 
The eight variables that had the highest predictive value that were then put into the 
nomogram were TSH, ultra sound (echo texture, shape and vascularity) with cytology 
(pseudo inclusions, nuclear grooving, cellularity in the background of colloid)(17). This 
nomogram was found to have a very good predictive accuracy and a good concordance index  
of  91 percent(17). 
 
 
(17) 
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(17) 
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Summary: 
 
The evaluation of a thyroid nodule often posts a challenge to the treating surgeon. If allowed 
to borrow a term from the evaluation of breast cancers, triple assessment would be the right 
terminology to use to describe thyroid nodule assessment.  A clear understanding of the 
clinical features, ultrasound findings and the implications of a FNA report is essential to the 
management of the thyroid nodule. 
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METHODS: 
 
All patients presenting with newly diagnosed nodule of thyroid were included in this study. 
Patients having external cytology / ultrasound were reassessed if agreeable to participate. 
Slide reviews were accepted if smears were considered adequate by the pathologists. All 
ultrasounds were repeated as the information that was required for this study maybe be 
inadequately reported from ultra sounds elsewhere.  Ultra sound guided FNACs were done if 
the clinicians felt it was required. 
Performa was filled either in the out patient department or after admission to the ward. The 
clinical assessment was done by a senior consultant. Most ultra sonograms were done by the 
designated radiologist, before the FNACs were done. 
Cytology was reported as per the Bethesda criteria. The gold standard for diagnosis in this 
study was taken as the histopathology result.  
The study was conducted in the time period between May 2011 and June 2012.  There were 
102 cases with malignant histopathology versus 93 cases of benign histopathology. 
The following clinical criteria were used to indicate increased risk of malignancy: 
• Age   >40 YRS  
• Male gender 
• Family history of thyroid malignancy 
• Persistent dysphonia, dysphagia or cough 
• Consistency - hard 
• Fixed swelling 
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FNAC CRITERIA: 
• I. Non diagnostic or Unsatisfactory 
• II. Benign 
• III. Atypia of Undetermined Significance or Follicular Lesion of Undetermined Significance 
• IV. Follicular Neoplasm or Suspicious for a Follicular Neoplasm 
• V. Suspicious for Malignancy 
• VI. Malignant 
ULTRA SOUND CRITERIA: 
• Punctate micro calcifications  
• Hypoechogenicity  
• Irregular margins or no halo 
• Solid/cystic/mixed 
• Intra nodule vascularity  
• More tall than wide 
• Lymph nodes - cystic 
 
The information was entered into Epi Data and analysed using SPSS after conversion to an excel 
spreadsheet. 
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RESULTS: 
 
Table 1 : Age distribution of cases 
 
Cases 
Total malignant benign 
age 15 - 40 No. 64 35 99 
% within age 64.6% 35.4% 100.0% 
41-50 No. 22 33 55 
% within age 40.0% 60.0% 100.0% 
>51 No. 16 25 41 
% within age 39.0% 61.0% 100.0% 
Total No. 102 93 195 
% within age 52.3% 47.7% 100.0% 
P value = 0.002 
 
 
 
 
 
 
59 
 
TAble 2: Sex distribution 
 
Cases 
Total malignant benign 
Sex female No. 69 64 133 
%  51.9% 48.1% 100.0% 
male No. 33 29 62 
%  53.2% 46.8% 100.0% 
Total No. 102 93 195 
%  52.3% 47.7% 100.0% 
P=0.861 
Table 3 : Features of compression or nerve involvement 
 
Cases 
Total malignant benign 
  Asymptomatic 85 76 161 
%  52.8% 47.2% 100.0% 
 Symptomatic 17 17 34 
%  50.0% 50.0% 100.0% 
Total Count 102 93 195 
%  52.3% 47.7% 100.0% 
P=0.767 
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Table 4: Dominant consistency 
Dominant consistency 
cases 
Total malignant benign 
  Hard 11 1 12 
%  91.7% 8.3% 100.0% 
 Soft 2 1 3 
%  66.7% 33.3% 100.0% 
 Cystic 0 3 3 
%  .0% 100.0% 100.0% 
 Firm 89 88 177 
%  50.3% 49.7% 100.0% 
                               
Total 
 102 93 195 
%  52.3% 47.7% 100.0% 
P=0.01 
 
 
 
 
61 
 
 
 
 
 
 
Table 5: Fixity to surrounding structures 
 
cases 
Total malignant benign 
fixity  No 98 93 191 
%  51.3% 48.7% 100.0% 
            Yes 4 0 4 
% 100.0% .0% 100.0% 
Total Count 102 93 195 
% 52.3% 47.7% 100.0% 
P=0.054 
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Table 6: FNAC 
FNAC  Benign  Malignant  Total 
Non diagnostic or un‐ 
satisfactory 
26 
(54.1%) 
23 
(47.9%) 
48 
Benign  41 
(66.1%) 
21 
(33.9%) 
62 
AUS  15 
(44.1%) 
19 
(55.9%) 
34 
 
Follicular neoplasm  9 
(39.1%) 
14 
(60.9%) 
23 
Suspicious  for 
malignancy 
1 
(8.3%) 
11 
(91.7%) 
12 
Malignant  0  15 
(100%) 
15 
P=0.00 
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Table 7: Punctate micro calcification on ultra sound 
Punctate micro calcification 
cases 
Total malignant benign 
  No 55 85 140 
%  39.3% 60.7% 100.0% 
 Yes 47 8 55 
%  85.5% 14.5% 100.0% 
Total  102 93 195 
%  52.3% 47.7% 100.0% 
P=0.000 
 
 
 
 
 
64 
 
 
 
 
Table 8: Hypoechogenicity 
Hypo echogenicity 
Cases 
Total malignant benign 
  No 55 62 117 
%  47.0% 53.0% 100.0% 
 Yes 47 31 78 
%  60.3% 39.7% 100.0% 
Total  102 93 195 
%  52.3% 47.7% 100.0% 
P=0.07 
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Table 9: Irregular margins 
Irregular margins 
cases 
Total malignant benign 
  No 89 87 176 
%  50.6% 49.4% 100.0% 
 Yes 13 6 19 
%  68.4% 31.6% 100.0% 
Total  102 93 195 
% 52.3% 47.7% 100.0% 
P=0.139 
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Table 10: Dominant consistency 
Consistency  Malignant  Benign  Total  P value 
Solid    Yes 
 
No 
47(71.2%) 
 
55(42.6%) 
19(28.8%)
 
74(57.4%) 
66 
 
129 
0.00
Cystic   Yes 
 
No 
3(23.1%) 
 
99(54.4%) 
10(76.9%) 
 
83(45.6%) 
13 
 
182 
0.029 
Mixed  Yes 
 
No 
55(45.8%) 
 
47(62.7%) 
65(54.2%) 
 
28(37.3%) 
120 
 
75 
0.022 
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Table12: Intra nodule vascularity 
Intra nodule vascularity 
Cases 
Total malignant benign 
 No  44 56 100 
%  44.0% 56.0% 100.0% 
Yes  58 37 95 
% 61.1% 38.9% 100.0% 
Total  102 93 195 
%  52.3% 47.7% 100.0% 
P=0.017 
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Table 13: More tall than wide 
More tall than wide 
cases 
Total malignant benign 
 No  87 75 162 
% 53.7% 46.3% 100.0% 
Yes  15 18 33 
%  45.5% 54.5% 100.0% 
Total No. 102 93 195 
%  52.3% 47.7% 100.0% 
P=0.387 
Table 14: Significant lymph nodes. 
Significant lymph nodes 
Cases 
Total malignant benign 
  No 75 88 163 
%  46.0% 54.0% 100.0% 
 Yes 27 5 32 
%  84.4% 15.6% 100.0% 
Total No. 102 93 195 
% 52.3% 47.7% 100.0% 
P=0.000 
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Table 15: Clinical size 
Size in cms 
Cases 
Total malignant benign 
size 0-3  46 33 79 
%  58.2% 41.8% 100.0% 
3-6  41 37 78 
%  52.6% 47.4% 100.0% 
>6 Count 15 23 38 
%  39.5% 60.5% 100.0% 
Total Count 102 93 195 
%  52.3% 47.7% 100.0% 
P=0.164 
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Table 16: Size by ultra sound 
 
Size in cms 
cases 
Total malignant benign 
size 0-3  52 51 103 
%  50.5% 49.5% 100.0% 
3-6  43 29 72 
%  59.7% 40.3% 100.0% 
>6  7 13 20 
% 35.0% 65.0% 100.0% 
Total  102 93 195 
%  52.3% 47.7% 100.0% 
P=0.1275 
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DISCUSSION: 
From Table 1, it is clear that most of our patients were in the age group 15 – 40 yrs. There 
were more number of benign thyroid swellings than malignant, which was statistically 
significant(P=0.002). 
 
 However, literature tells us that malignant swellings are common in the younger and older 
extremes of age(9). This is not reflected here in this study. It could be because, there were 
lesser number of patients in the >50yrs age groups.  
 
Table 2 shows us that there were more number of females enrolled into the study than males. 
But the number of benign and malignant thyroid swellings were almost equally distributed in 
the male group.  
 
This is contrary to literature that tells us that being of male sex is a risk factor for 
malignancy(9). 
 
Table 3 tells us that even though traditionally features of compression or nerve involvement 
have been considered as features of malignancy, it may not be the case. 
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Table 4,5 and 6 shows us that hard consistency, fixity are definite risk factors for malignancy 
with a significant P values. 
 
Table 7 tells us how the Bethesda criteria works with the Indian population. There were a 
large number of  non diagnostic or unsatisfactory FNACs. The percentage of malignancy was 
47.9% .  
 
Literature describes the risk of malignancy in the non diagnostic or unsatisfactory FNACs to 
be  1 -  4%(12). The high number of ND/US FNACs may be because most of these FNAs are 
not done ultra sound guided and done by relatively inexperienced residents, at an early stage 
of their surgical training. 
 
There were also a large number of cases reported as benign in the FNAC, in which the final 
histopathology report was malignant(33.9%). The risk as reported by the Bethesda criteria 
was 0-3%(12). 
 
The atypia of undetermined significance(AUS) group has always been of interest to 
researchers all over the world. There were 34 cases in this group of which, 19 were malignant 
ie; 55.9%.  
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The suspicious of malignancy and malignancy group percentages were in keeping with the 
Bethesda criteria(12). 
 
From tables 8, 9, 10, 11, 12, 13, 14, we can infer that the punctuate micro calcifications, hypo 
echogenicity, intra nodule vascularity and significant lymph nodes are risk factors to indicate 
malignancy. A solid consistency of the nodule is a risk factor for malignancy while a cystic 
nature indicates that it is more likely benign. 
 
Tables 15, 16 tell us that size may not be a significant risk factor for malignancy inspite of 
iterature telling us otherwise.(2) 
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CONCLUSIONS: 
 
1) Older age and male gender were not  risk factors for malignancy. 
2) Features of compression was not  a risk factor for malignancy. 
3) Hard consistency, fixity were definite risk factors for malignancy. 
4) The Bethesda system will need further validation among the Indian population.  
5) FNACs have better yield and clinical value when done ultra sound guided than 
manually. 
6) Ultra sound features that are significant are punctuate micro calcifications, hypo 
echogenicity, intra nodule vascularity, solid consistency and significant lymph nodes. 
7) Size was not  a risk factor for malignancy in this study 
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LIMITATIONS: 
This study was conducted in a single centre. As evident above, the sonological features and 
clinical assessment of a thyroid nodule is very observer independent. An ideal study design 
would be to involve multiple centres and a wide demography of patients.  
 
In spite of best efforts to make a single radiologists do all the ultra sonograms, we had to 
succumb to the impossible logistics of the above proposition. This being a teaching centre 
and because of the sheer load of ultra sonograms that are done in a single day by the 
Department of Radiology, we had to accept that different radiologists could do the ultra 
sonogram as long as they adhere to the Proforma that we had given them for the thyroid ultra 
sound. 
 
Previous similar studies have had a large sample size. Most have been retrospective studies 
making it much easier to acquire a large sample size. However, this was a prospective study, 
over a period of one and a half years, making it difficult to attain a larger sample size. No 
doubt, a larger sample size would have increased the significance of the study. 
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CONSENT: 
I understand that I am taking part in a research study on thyroid nodules. My participation in the study is until I get my final 
histopathology report after surgery. Taking part in this study does not involve any tests other than which I would normally 
undergo as a part of evaluation of my thyroid nodule. The risks and unforeseen complications of taking part in this study is 
the same as any other non study patient. I also understand that my records will be kept confidential and only the author of 
this study will have access to it. My participation is voluntary, and i can withdraw from the study at any time and that 
refusal to participate will not involve any penalty or loss of benefit. 
All of the above has been explained to me in my own language. 
আিম বঝুেত পাির  ĺয আিম eকǅ থাiরেয়ড nodules গেবষণা গেবষণায় aংশ  িনিc. গেবষণায় আমার aংশgহণ পযŪn আিম aেstাপচােরর পর আমার histopathology  চূŔাn 
pিতেবদন  ĺপেত. ei গেবষণায় aংশ  ĺনoয়ার  ĺকােনা পরীkা বƟতীত aনƟ যা সাধারণত আিম আমার থাiরেয়ড aবুŪদ মূলƟায়ন eকǅ aংশ  িহসােব সহƟ করা হেব সেǩ যkু নয়.  ঝঁুিক ei 
গেবষণায় aংশ gহণ eবং aভািবত জǅলতা ĺথেক নন aধƟয়ন ĺরাগী িহসােব eকi. আিম বঝুেত পাির ĺয আমার ĺরকডŪ  রাখা ĺগাপন করা হেব eবং শধুমুাt ei গেবষণার ĺলখক eǅ aƟােkস 
থাকেব. আমার aংশgহণ ĺscােসবী, eবং আিম ĺকান সময় eবং ĺয asীকার ĺকান লাভ বা kিত শািs না জিŔত করা হেব aংশgহণ e গেবষণা ĺথেক িনেজেক pতƟাহার করেত পােরন. 
uপেরাk সমs সmেকŪ  যাo কেরিন আমার িনেজর ভাষায় বƟাখƟা করা হেয়েছ. 
                              . 
                         
      .                 
                             
           .     
              
   .               
         .    ,  
                  
          . 
           . 
                 
.                 
          .           
         
     .      
       .    
                   
  .                   
                   
  . 
      . 
 
Patient’s Sign:                                                                                   Doctor’s sign: 
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PATIENT INFORMATION SHEET: 
This sheet is to give you a basic idea of the study that you are part off. This study is on thyroid nodules. At present, there is 
no way to predict the likelihood of cancer in your thyroid swelling. The aim of this study is to form a scoring system to 
predict cancer. All the information will be collected in the form of clinical examination, ultra sound neck and FNAC neck. 
There is another proforma that we will be filling once the results of your test are out. These are the investigations that any 
patient with a thyroid nodule will undergo. You will not be subjected to any extra investigations or your treatment will not 
be compromised in any way. All the information collected for this study will be kept confidential and patient identity will 
not be revealed.  However, for the sake of furtherment of science, the results may have to be published in international, 
national journals. If at any point you wish to withdraw from the study, you are free to do so. Contact information for any 
doubts that you may have are given below. 
 रोगी सूचना पऽक: 
इस पऽक के िलए आप अÚययन है Ǒक आप Ǒहःसा बंद कर रहे हɇ कȧ एक बुिनयादȣ ǒवचार दे रहा है.इस अÚययन थायरॉयड ǒपंड पर 
है. वत[मान मɅ, वहाँ कोई अपने थाइरोइड सूजन मɅ कɇ सर कȧ संभावना का अनुमान है. इस अÚययन का उƧेँय के िलए एक ःकोǐरंग 
ूणाली के िलए कɇ सर कȧ भǒवंयवाणी Ǿप है. सभी imformation नैदािनक परȣ¢ा, अãशा Úविन गद[न और FNAC गद[न के Ǿप मɅ 
एकऽ Ǒकया जाएगा. इन जांच Ǒक एक थायरॉयड मंिथ के साथ Ǒकसी भी मरȣज से गुजरना होगा. आप Ǒकसी भी अितǐरƠ जांच के 
अधीन नहȣं होगा. सभी इस अÚययन के िलए एकǒऽत कȧ गई जानकारȣ को गोपनीय रखा जाए और रोगी कȧ पहचान उजागर नहȣं 
Ǒकया जाएगा. हालांǑक, ǒव£ान कȧ furtherment कȧ खाितर, पǐरणाम के िलए अंतरा[ƶीय, राƶीय पǒऽकाओ ंमɅ ूकािशत Ǒकया जा 
सकता है. Ǒकसी भी ǒबंद ुपर यǑद आप अÚययन से वापस चाहते हɇ, तो आप ऐसा करने के िलए ःवतंऽ हɇ. 
          .   
  . ,     
     .    
      .   
 ,     FNAC   
.         
 .          
.        
    . 
           
  . ,  furtherment , , 
    .    
    ,   .  
     . 
ei পtেক আপিন eকǅ গেবষণা uপজীবƟ ĺয আপিন বn aংশ িদেত হয়. ei চচŪ া থাiরেয়ড nodules হয়. বতŪ মােন, ĺকান uপায় আপনার ফুেল থাiরেয়ড কƟাnার সmাবনা ভিবষƟdাণী করা হয়. ei 
গেবষনার uেdশƟ eকǅ ĺsািরং িসেsেমর কƟাnার গঠন ভিবষƟdাণী করা হয়. সমs তথƟ িkিনকাল পরীkা, aিত শb ঘাŔ eবং FNAC ঘাŔ ফমŪ সংgহ করা হেব. aনƟ দশŪনাথŪ পযŪn ĺয আমরা ভিতŪ  
eকবার আপনার পরীkার ফলাফল আuট করা হেব. eগিুল হল ĺয eকǅ তদn থাiরেয়ড aবুŪদ সেǩ ĺকােনা ĺরাগীর সহƟ করা হেব. আপিন aিতিরk ĺকােনা তদn যাo চলেছ করা হiিন বা আপনার িচিকƄসা 
ĺকােনা ভােব আেপাস করা হেব না. সমs তথƟ ei aধƟয়েনর জনƟ সংগহৃীত রাখা ĺগাপনীয় eবং ĺরাগীর পিরচয় pকাশ করা হেব না হেব. 
  িবjান furtherment aনেুরােধ জনƟ যাiেহাক, ফলাফল আnজŪ ািতক pকািশত করা হেব জাতীয় পিtকা আেছ, হেত পাের. যিদ ĺকান িবnু আপিন গেবষণা ĺথেক িনেজেক pতƟাহার করেত চান, তাহেল হয় 
ĺসটা িবনামূেলƟ. ĺকােনা সেnহ জনƟ ĺয তথƟ আপিন পােরন িনেচ ĺদoয়া আেছ সােথ ĺযাগােযাগ করুন. 
Contact information:  
Dr. Vimalin Samuel 
PG Registrar,  Department of endocrine surgery, Cmc, Vellore, Mobile no: 9894180990 
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            CHRISTIAN MEDICAL COLLEGE, VELLORE 
TRIPLE ASSESSMENT OF SOLITARY NODULE OF THYROID 
NAME:                                                     HOSPITAL NUMBER: or BRADMA: 
DATE ( OF FIRST ASSESSMENT): 
CLINICAL ASSESSMENT: 
•  AGE:            (1) 15‐40yrs         (2)40=50 yrs        (0) >50yrs 
• SIZE OF NODULE:  
• SEX:              (1) MALE                     (0)FEMALE 
• FAMILY HISTORY OF THYROID MALIGNANCY     (1) Y         (0) N0 
• PERSISTENT DYSPHONIA, DYSPHAGIA OR COUGH    (1) Y        (0) N 
• DOMINANT CONSISTENCY – (1) HARD   (2) CYSTIC   (3) SOFT 
• FIXED SWELLING     (1) Y    (0) N 
EXTRA THYROID EXTENSION     (1) Y     (0) N 
FNAC: ( TO BE DONE FROM THE BODY OF THE FNAC REPORT) 
            (1) Non diagnostic or Unsatisfactory 
Cyst fluid only               Acellular specimen                  Other (obscuring blood, clotting artifact, etc)  
            (2) Benign    
Consistent with a benign follicular nodule (includes adenomatoid nodule, colloid nodule, etc) 
Consistent with lymphocytic (Hashimoto) thyroiditis  
Consistent with granulomatous (subacute) thyroiditis  
others 
             (3) Atypia of Undetermined Significance or Follicular Lesion of Undetermined Significance  
             (4)Follicular Neoplasm or Suspicious for a Follicular Neoplasm 
Hürthle cell (oncocytic) type              
             (5) Suspicious for Malignancy 
                Suspicious for papillary carcinoma             Suspicious for medullary carcinoma 
               Suspicious for metastatic carcinoma            Other 
 
           (6) Malignant 
               Papillary thyroid carcinoma             Poorly differentiated carcinoma         Medullary thyroid carcinoma 
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              Undifferentiated (anaplastic) carcinoma         Squamous cell carcinoma 
              Carcinoma with mixed features: follicular variant of papillary 
              Metastatic carcinoma  Non‐Hodgkin lymphoma 
              Other 
ULTRA SOUND ASSESSMENT: 
Punctate microcalcifications     (1) Y  (0)N                                      Hypoechogenicity  (1) Y    (0)N 
Irregular margins or no halo  (1) Y  (0) N                                        Solid      (1)Y   (0)N 
Cystic    (1)Y   (0)N                                                                              Mixed    (1)Y  (0)N 
Intranodule vascularity   (1)Y       (0)N                                             More tall than wide   (1)Y  (0)N 
Lymph Node / Cystic  (1)Y  (0)N                                                        Size  
HISTOPATHOLOGY:  
                Malignant: (1) y      (0) n 
Papillary thyroid carcinoma                Poorly differentiated carcinoma         Medullary thyroid carcinoma 
Undifferentiated (anaplastic) carcinoma   Squamous cell carcinoma 
Carcinoma with mixed features (specify)    Metastatic carcinoma 
Non‐Hodgkin lymphoma            Nodular with carcinoma         Hashimoto’s with carcinoma 
BENIGN: 
nodular    Cyst    Hashimoto’s 
CONSENT: 
I understand that I am taking part in a research study on thyroid nodules. My participation in the study if until I 
get my final histopathology report after surgery. Taking part in this study does not involve any tests other than 
which I would normally undergo as a part of evaluation of my thyroid nodule. The risks and unforeseen 
complications of taking part in this study is the same as any other non study patient. I also understand that my 
records will be kept confidential and only the author of this study will have access to it. My participation is 
voluntary, and i can withdraw from the study at any time and that refusal to participate will not involve any 
penalty or loss of benefit. 
All of the above has been explained to me in my own language. 
Sign:                                                                                   Doctor’s sign: 
                                                                                            Name of doctor: 
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